Novo Nordisk CEO steps down amid market challenges, including competition from Eli Lilly's rival drug and setbacks with Novo Nordisk's obesity treatments.
Novo Nordisk CEO steps down amid market challenges, including competition from Eli Lilly's rival drug and setbacks with Novo Nordisk's obesity treatments.